Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it ...

Markets expect rate cuts — but your earnings don’t have to suffer. Lock in 7.2% until 2028 from ten individual bonds. Based ...

The U.S. Food and Drug Administration approved the vaccine, Nuvaxovid, but limited its use to older adults and people over 12 ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

Fintel reports that on May 14, 2025, Leerink Partners downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labelled ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Johnson & Johnson (NYSE:JNJ) stock and Halozyme (HALO) stock were downgraded at Leerink Partners on earlier than expected price controls for products. Read more here.

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

On Tuesday, Leerink Partners adjusted its stance on Johnson & Johnson (NYSE:JNJ) stock, downgrading it from Outperform to Market Perform. The firm also lowered its price target to $153 from the ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (BMV:HALO) from Market Perform to Underperform. There are 607 funds or institutions ...